glucose, (beta-d)-isomer has been researched along with Heart Diseases in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (14.29) | 18.7374 |
| 1990's | 1 (4.76) | 18.2507 |
| 2000's | 1 (4.76) | 29.6817 |
| 2010's | 5 (23.81) | 24.3611 |
| 2020's | 11 (52.38) | 2.80 |
| Authors | Studies |
|---|---|
| Cook, DN; Kotwal, GJ; Miller, CG | 1 |
| Cao, Y; Chen, X; Chu, C; Delic, D; Frankenreiter, S; Gaballa, MMS; Hasan, AA; Hocher, B; Klein, T; Krämer, BK; Luo, T; Stadermann, K; Xiong, Y; Xue, Y; Yin, L; Zeng, S | 1 |
| Abdulrahman, N; Eldassouki, H; Gadeau, AP; Imran, Z; Ismail, R; Moustafa, DA; Mraiche, F; Rayan, M | 1 |
| Chen, J; Huang, Y; Li, T; Lin, X; Lin, Y; Lu, H; Xian, J; Yang, Z; Zhang, Q | 1 |
| Alam, MJ; Arava, S; Banerjee, SK; Bugga, P; Katare, P; Maulik, SK; Meghwani, H; Mohammed, SA | 1 |
| Baker, HE; Goodwill, AG; Mather, KJ; Tune, JD | 1 |
| Braam, B; Byrne, NJ; Darwesh, AM; Dyck, JRB; El-Kadi, AOS; Ferdaoussi, M; Jahng, JWS; Levasseur, JL; Light, PE; Maayah, ZH; Matsumura, N; Parajuli, N; Seubert, JM; Sweeney, G; Takahara, S; Verma, S; Vos, D; Young, ME | 1 |
| Gao, X; Li, R; Liu, R; Shi, H; Yan, F; Zhuang, X | 1 |
| Ferreira, JP; Fitchett, D; George, J; Inzucchi, SE; Lauer, S; Ofstad, AP; Verma, S; Wanner, C; Zinman, B; Zwiener, I | 1 |
| Barış, VÖ; Dinçsoy, AB; Erdem, A; Gedikli, E; Müftüoğlu, S; Zırh, S | 1 |
| Droebner, K; Eitner, F; Freyberger, A; Hartmann, E; Hüser, J; Joseph, A; Kolkhof, P; Mathar, I; Pavkovic, M; Sandner, P | 1 |
| Altucci, L; Barbieri, A; Botti, G; Canale, ML; Carbone, A; Conte, M; De Laurentiis, M; Maurea, N; Monti, MG; Paccone, A; Quagliariello, V; Rea, D | 1 |
| Calvenzani, V; Fornari, M; Giorgio, M; Marinelli, A; Matros, A; Micheli, LA; Mock, HP; Petroni, K; Pilu, R; Tonelli, C; Trinei, M | 1 |
| Ma, X; Ma, Y; Pan, X; Wu, Z | 1 |
| Hishida, A; Hosoda, K; Koezuka, R; Makino, H; Matsuo, M; Miyamoto, Y; Ohata, Y; Son, C; Tamanaha, T; Tochiya, M; Tomita, T; Yasuda, S | 1 |
| Ledford, H | 1 |
| Wang, JL; Wang, WQ; Zhang, SH | 1 |
| Freischmidt, A; Heilmann, J; Kelber, O; Koptina, A; Müller, J; Sadeghlar, F; Ulrich-Merzenich, G; Wagner, H; Zeitler, H | 1 |
| CLOETENS, W; DE MEY, D | 1 |
| PERALE, L | 1 |
| COVA, N; FERRARI, E | 1 |
1 review(s) available for glucose, (beta-d)-isomer and Heart Diseases
| Article | Year |
|---|---|
Evaluating the effects of sodium glucose co-transporter -2 inhibitors from a renin-angiotensin-aldosterone system perspective in patients infected with COVID-19: contextualizing findings from the dapagliflozin in respiratory failure in patients with COVID
Topics: Angiotensin-Converting Enzyme 2; Benzhydryl Compounds; Clinical Trials, Phase III as Topic; COVID-19; Double-Blind Method; Drug Repositioning; Glucosides; Heart Diseases; Humans; Kidney Diseases; Mitochondria; Multicenter Studies as Topic; Oxidative Stress; Randomized Controlled Trials as Topic; Receptors, Virus; Renin-Angiotensin System; Respiratory Insufficiency; SARS-CoV-2; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
1 trial(s) available for glucose, (beta-d)-isomer and Heart Diseases
| Article | Year |
|---|---|
Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial.
Topics: Aged; Atherosclerosis; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Female; Glucosides; Heart Diseases; Humans; Kidney Diseases; Male; Metabolic Syndrome; Middle Aged; Risk Assessment; Risk Factors; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome | 2020 |
19 other study(ies) available for glucose, (beta-d)-isomer and Heart Diseases
| Article | Year |
|---|---|
Two chemotactic factors, C5a and MIP-1alpha, dramatically alter the mortality from zymosan-induced multiple organ dysfunction syndrome (MODS): C5a contributes to MODS while MIP-1alpha has a protective role.
Topics: Animals; Chemical and Drug Induced Liver Injury; Chemokine CCL3; Chemokine CCL4; Chemotactic Factors; Complement C5a; Female; Heart Diseases; Liver Diseases; Lung Diseases; Lymphatic Diseases; Macrophage Inflammatory Proteins; Male; Mice; Mice, Knockout; Multiple Organ Failure; Syndrome; Zymosan | 1996 |
Antifibrotic effects of low dose SGLT2 Inhibition with empagliflozin in comparison to Ang II receptor blockade with telmisartan in 5/6 nephrectomised rats on high salt diet.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Benzhydryl Compounds; Dose-Response Relationship, Drug; Fibrosis; Glucosides; Glycosuria; Heart Diseases; Iron; Kidney Diseases; Male; Nephrectomy; Rats; Rats, Wistar; Sequence Analysis, RNA; Sodium-Glucose Transporter 2 Inhibitors; Sodium, Dietary; Telmisartan | 2022 |
SGLT2 inhibitor dapagliflozin attenuates cardiac fibrosis and inflammation by reverting the HIF-2α signaling pathway in arrhythmogenic cardiomyopathy.
Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Benzhydryl Compounds; Cardiomyopathies; Collagen; Diabetes Mellitus, Type 2; Fibrosis; Glucose; Glucosides; Heart Diseases; Inflammation; Mice; NF-kappa B; Signal Transduction; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Empagliflozin prohibits high-fructose diet-induced cardiac dysfunction in rats via attenuation of mitochondria-driven oxidative stress.
Topics: Animals; Benzhydryl Compounds; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet; Fibrosis; Fructose; Glucose; Glucosides; Heart Diseases; Insulin Resistance; Mitochondria; Oxidative Stress; Palmitates; Palmitic Acid; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2022 |
Benefits of Empagliflozin Beyond Enhancing Myocardial Energetics?
Topics: Animals; Benzhydryl Compounds; Energy Metabolism; Glucosides; Heart Diseases; Hemodynamics; Humans; Myocardium; Oxygen Consumption; Sodium-Glucose Transporter 2 Inhibitors; Swine | 2019 |
Empagliflozin Blunts Worsening Cardiac Dysfunction Associated With Reduced NLRP3 (Nucleotide-Binding Domain-Like Receptor Protein 3) Inflammasome Activation in Heart Failure.
Topics: Animals; Benzhydryl Compounds; Carrier Proteins; Glucosides; Heart Diseases; Heart Failure; Inflammasomes; Male; Mice, Inbred C57BL; NLR Family, Pyrin Domain-Containing 3 Protein; Nucleotides; Stroke Volume | 2020 |
Salidroside Attenuates Doxorubicin-Induced Cardiac Dysfunction Partially Through Activation of QKI/FoxO1 Pathway.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Cardiotoxicity; Cell Line; Disease Models, Animal; Doxorubicin; Forkhead Box Protein O1; Glucosides; Heart Diseases; Male; Mice, Inbred C57BL; Myocytes, Cardiac; Nerve Tissue Proteins; Oxidative Stress; Phenols; Rats, Sprague-Dawley; Reactive Oxygen Species; RNA-Binding Proteins; Signal Transduction; Ventricular Function, Left | 2021 |
Empagliflozin Significantly Prevents the Doxorubicin-induced Acute Cardiotoxicity via Non-antioxidant Pathways.
Topics: Action Potentials; Animals; Benzhydryl Compounds; Cardiotoxicity; Cell Proliferation; Disease Models, Animal; Doxorubicin; Glucosides; Heart Diseases; Heart Rate; Male; Mitochondria, Heart; Myocytes, Cardiac; Rats, Sprague-Dawley; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Ventricular Function, Left | 2021 |
Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage.
Topics: Animals; Benzhydryl Compounds; Disease Models, Animal; Drug Combinations; Female; Glucosides; Heart Diseases; Hypertension; Kidney Diseases; Naphthyridines; Rats; Sodium-Glucose Transporter 2 Inhibitors | 2021 |
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin.
Topics: Animals; Anti-Inflammatory Agents; Antifibrotic Agents; Apoptosis; Benzhydryl Compounds; Cardiotoxicity; Cell Line; Cytokines; Disease Models, Animal; Doxorubicin; Female; Ferroptosis; Fibrosis; Glucosides; Heart Diseases; Inflammasomes; Inflammation Mediators; Mice, Inbred C57BL; Myeloid Differentiation Factor 88; Myocytes, Cardiac; NLR Family, Pyrin Domain-Containing 3 Protein; Signal Transduction; Sodium-Glucose Transporter 2 Inhibitors; Ventricular Function, Left | 2021 |
Dietary cyanidin 3-glucoside from purple corn ameliorates doxorubicin-induced cardiotoxicity in mice.
Topics: Animal Feed; Animals; Anthocyanins; Cardiotoxicity; Cell Survival; Cytoprotection; Diet; Disease Models, Animal; Dose-Response Relationship, Drug; Doxorubicin; Female; Gene Expression Regulation; Glucosides; Heart Diseases; HeLa Cells; Humans; MCF-7 Cells; Mice, Inbred C57BL; Myocytes, Cardiac; Phytotherapy; Plant Extracts; Plants, Medicinal; Protective Agents; Time Factors; Zea mays | 2017 |
[Polydatin ameliorates myocardial fibrosis in rats by up-regulating SIRT3 and SDF-1].
Topics: Animals; Chemokine CXCL12; Fibrosis; Glucosides; Heart Diseases; Male; Rats; Rats, Sprague-Dawley; Sirtuin 1; Sirtuin 3; Stilbenes; Superoxide Dismutase | 2018 |
Effect of tofogliflozin on cardiac and vascular endothelial function in patients with type 2 diabetes and heart diseases: A pilot study.
Topics: Aged; Benzhydryl Compounds; Diabetes Mellitus, Type 2; Endothelial Cells; Female; Glucosides; Heart Diseases; Humans; Male; Middle Aged; Pilot Projects; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome; Ventricular Function, Left | 2020 |
Diabetes drugs ride a bumpy road.
Topics: Benzhydryl Compounds; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus; Glucosides; Heart Diseases; Humans; Hypoglycemic Agents; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Weight Loss | 2013 |
Protective effect of tetrahydroxystilbene glucoside on cardiotoxicity induced by doxorubicin in vitro and in vivo.
Topics: Animals; Animals, Newborn; Antibiotics, Antineoplastic; Apoptosis; Calcium; Cardiotonic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Doxorubicin; Glucosides; Heart Diseases; Male; Mice; Myocytes, Cardiac; Rats; Reactive Oxygen Species; Signal Transduction; Stilbenes | 2009 |
Prediction of adverse events by in vivo gene expression profiling exemplified for phytopharmaceuticals containing salicylates and the antidepressant imipramine.
Topics: Animals; Antidepressive Agents, Tricyclic; Benzyl Alcohols; Chemical and Drug Induced Liver Injury; Ethanol; Gene Expression Profiling; Gene Expression Regulation; Glucosides; Heart Diseases; Hypertension, Pulmonary; Imipramine; Male; Nephritis; Phytotherapy; Plant Bark; Plant Extracts; Rats; Rats, Sprague-Dawley; Salicylates | 2012 |
[Clinical use of khellol-glucoside].
Topics: Anti-Arrhythmia Agents; Cardiotonic Agents; Glucosides; Glycosides; Heart Diseases; Humans; Khellin | 1954 |
[The use of C-glucoside of digitalis lanata in pediatrics].
Topics: Child; Digitalis; Digitalis Glycosides; Glucosides; Heart Diseases; Humans; Infant; Pediatrics; Therapeutic Uses | 1954 |
[PRACTICAL CONCEPTS OF DIGITALIS THERAPY. CLINICAL TRIALS WITH A RAPIDLY EXCRETED GLUCOSIDE: DIGOXIN].
Topics: Biomedical Research; Digitalis; Digitalis Glycosides; Digoxin; Geriatrics; Glucosides; Heart Diseases; Humans | 1964 |